Special Issue

Advanced Research of HLA in Diseases

Message from the Guest Editor

Recently, scientific research has established strong relationships between specific HLA alleles and different diseases. Early studies focused on the relationship between ankylosing spondylitis and HLA-B*27 underlying the immunogenetic background of this disorder. Other works have demonstrated connections between HLA genes and autoimmune diseases. The HLA gene complex has also been positively associated with the risk of infectious disease onset and development like in chronic hepatitis C virus infection: HLA A*23:01, B*44:02, C*04:02. Other significant associations include examples like chronic renal diseases: B*40, C*12, C*15, and DRB1*14. Chronic lymphocytic leukemia has been associated with HLA-DRB1*04:02:01 and HLA-DRB3*02:01:01. HLA-B*57:01 is associated with drug hypersensitivity to carbamazepine and abacavir. This evidence illustrates the significant role of HLA genes in diseases. Further research is needed for a better understanding of the molecular mechanisms underlying these associations with specific HLA molecules.

Guest Editor

Prof. Dr. Ileana Constantinescu

1. Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 022328 Bucharest, Romania

Deadline for manuscript submissions

closed (30 April 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/si/189644

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).